Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.513 | A Pilot Study to Establish a Local Next-Generation Sequencing (NGS) Platform Enhanced with Artificial Intelligence (AI) For high Throughput Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.523 | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.020 | A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.626 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2017.172 | DETECTION AND QUANTIFICATION OF T790M and C797S MUTATIONS VIA DIGITAL DROPLET POLYERMASE CHAIN REACTION (ddPCR) IN LUNG CANCER PATIENTS ON OSIMERTINIB TREATMENT |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2017.347 | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2016.493 | An Open-Label, Multicenter, Phase 1 Study with Expansion Cohorts of Ramucirumab or Necitumumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer after Progression on First-Line EGFR TKI Therapy |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2016.104 | A retrospective review of Epidemiology, Treatment Patterns, Prognostic Factors and Survival Outcomes of Sarcoma patients in Hong Kong | Dr. LOONG Herbert Ho Fung |
| 2016.076 | An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.074 | A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.651 | A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2021.497 | A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2023.069 | A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) | Dr. LOONG Herbert Ho Fung |
| 2022.654 | A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) | Dr. LOONG Herbert Ho Fung |
| 2022.172 | KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2022.261 | A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors | Dr. LOONG Herbert Ho Fung |
| 2021.456 | A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2021.540 | TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2023.067 | Long-term survivorship challenges of advanced/metastatic GIST patients responding to tyrosine kinase inhibitor treatment: An observational study. | Dr. LOONG Herbert Ho Fung |
| 2022.272 | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2021.582 | An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation | Dr. LOONG Herbert Ho Fung |
| 2023.038 | (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS | Dr. LOONG Herbert Ho Fung |
| 2022.070 | A Phase 2, Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.341 | A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2023.150 | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2021.399 | PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01) |
Dr LOONG Herbert Ho Fung 龍浩鋒 |
| 2024.319 | An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Dr. LOONG Herbert Ho Fung |
| 2024.248 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | Dr. LOONG Herbert Ho Fung |
| 2024.269 | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. | Dr. LOONG Herbert Ho Fung |
| 2024.425 | An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors | Dr. LOONG Herbert Ho Fung |
| 2015.155 | A multicenter randomized, open-label, phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2015.632 | A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.518 | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.585 | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed following Definitive, Platinum-Based, Chemoradiation Therapy (PACIFIC 5) |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2019.609 | A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF OZURIFTAMAB VEDOTIN (BA3021) ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Dr. LOONG Herbert H.F. |
| 2020.515 | Determining Engrailed-2 (EN2) Concentration in Urine Samples for Clinical Development of a Urine Lateral Flow Assay for Screening Urinary Tract Cancers |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2018.422 | A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2020.197 | Blood-based Technology for the Detection of Epidermal Growth Factor Receptor Exon 20 Insertion in Patients with Advanced Stage Lung Cancer | Dr. LOONG Herbert |
| 2014.457 | A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer | Prof. LOONG Herbert |
| 2015.257 | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine |
Dr. LOONG Herbert 龍浩鋒 |
| 2016.164 | A PILOT RANDOMIZED OPEN-LABELED STUDY COMPARING A STRUCTURED TITRATION METHOD OF IMMEDIATE- AND SUSTAINED-RELEASE OXYCODONE VERSUS OPIOIDS TITRATION OF INVESTIGATORS’ CHOICE IN ADVANCED CANCER PATIENTS IN HONG KONG | Dr. LOONG Herbert |
| 2016.162 | A Feasibility Study Investigating the Presence of Intra- and Inter-tumoural Heterogeneity in Gastrointestinal Stromal Tumours and Its Potential Impact on Treatment Response, Monitoring and Patients’ Survival | Dr. LOONG Herbert |
| 2016.165 | An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma |
Dr. LOONG Herbert 龍浩鋒 |
| 2016.625 | A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors |
Dr. LOONG Herbert 龍浩鋒 |
| 2021.495 | Reduction of Polypharmacy in Frail Elderly Patients in Hong Kong Using STOPPFrail Criteria |
Dr LOO Chi Wah 盧志華 |
| 2024.038 | Deciphering the role of macrophage metabolic reprogramming in immunotherapy resistance of non-alcoholic steatohepatitis-hepatocellular carcinoma | Dr. LONG Xiaohang |
| 2019.468 | The prevalence of chromosomal abnormalities in fetuses with different degree of cerebral ventriculomegaly and the association of neurodevelopmental outcome after birth | Dr. LOK Wing Yi |
| 2017.654 | Deep learning algorithm for the detection of of diabetic retinopathy and/or age-related macular degeneration in a Chinese population |
Dr. LOK Ka Hing 駱家慶 |
| 2015.167 | Evaluating effect of strabismus surgery on reading-related skills in Chinese school-aged children with intermittent exotropia and constant exotropia |
Dr. LOK Julie Ying Ching 駱映晴 |
Page 100 of 254.